Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma
Gilles Crochet, Gloria Iacoboni, Audrey Couturier, Emmanuel Bachy, Josu Iraola‐Truchuelo, Thomas Gastinne, Guillaume Cartron, Tom Fradon, Bastien Lesne, Mi Kwon, Romain Gounot, Núria Martínez‐Cibrián, Cristina Castilla‐Llorente, Pau Abrisqueta, Manuel Guerreiro, Clémentine Sarkozy, José María Aspa-Cilleruelo, Vincent Camus, Stéphanie Guidez, Adrien Chauchet, Éric Deconinck, Krimo Bouabdallah, Francesc Bosch, Pere Barba, Franck Morschhauser, Roch Houot
Abstract
ABSTRACT: In this retrospective study, chimeric antigen receptor T cells remained effective in patients with relapsed/refractory large B-cell lymphoma after prior exposure to bispecific antibodies (BsAbs) targeting different antigens. These results are relevant to clinical practice, particularly given the increasing use of BsAbs in earlier treatment lines.